Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission

NCT01465386 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01465386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01465386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2011
Completion date
March 2, 2015
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute minimally differentiated myeloid leukemia (m0), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute promyelocytic leukemia (m3), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), secondary acute myeloid leukemia